Form 8-K - Current report:
SEC Accession No. 0000950170-24-115596
Filing Date
2024-10-18
Accepted
2024-10-18 16:05:07
Documents
11
Period of Report
2024-10-15
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K inkt-20241015.htm   iXBRL 8-K 35781
  Complete submission text file 0000950170-24-115596.txt   152314

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT inkt-20241015.xsd EX-101.SCH 25843
13 EXTRACTED XBRL INSTANCE DOCUMENT inkt-20241015_htm.xml XML 4885
Mailing Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010
Business Address 149 FIFTH AVENUE SUITE 500 NEW YORK NY 10010 212-994-8250
MiNK Therapeutics, Inc. (Filer) CIK: 0001840229 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40908 | Film No.: 241380784
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)